nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—Skin candida—Epirubicin—liver cancer	0.036	0.0368	CcSEcCtD
Linezolid—Skin candida—Doxorubicin—liver cancer	0.0333	0.034	CcSEcCtD
Linezolid—Amylase increased—Sorafenib—liver cancer	0.0236	0.0241	CcSEcCtD
Linezolid—Transient ischaemic attack—Sorafenib—liver cancer	0.0223	0.0227	CcSEcCtD
Linezolid—Lactic acidosis—Epirubicin—liver cancer	0.017	0.0174	CcSEcCtD
Linezolid—Lactic acidosis—Doxorubicin—liver cancer	0.0157	0.0161	CcSEcCtD
Linezolid—Glossitis—Sorafenib—liver cancer	0.0122	0.0125	CcSEcCtD
Linezolid—Drug interaction—Sorafenib—liver cancer	0.0121	0.0124	CcSEcCtD
Linezolid—Neuropathy—Sorafenib—liver cancer	0.0105	0.0108	CcSEcCtD
Linezolid—Fungal skin infection—Epirubicin—liver cancer	0.00993	0.0102	CcSEcCtD
Linezolid—Laboratory test abnormal—Epirubicin—liver cancer	0.00993	0.0102	CcSEcCtD
Linezolid—Fungal skin infection—Doxorubicin—liver cancer	0.00919	0.0094	CcSEcCtD
Linezolid—Laboratory test abnormal—Doxorubicin—liver cancer	0.00919	0.0094	CcSEcCtD
Linezolid—Cardiac failure congestive—Sorafenib—liver cancer	0.00899	0.00919	CcSEcCtD
Linezolid—Myelosuppression—Epirubicin—liver cancer	0.00885	0.00904	CcSEcCtD
Linezolid—Peripheral vascular disorder—Epirubicin—liver cancer	0.00846	0.00865	CcSEcCtD
Linezolid—Rectal disorder—Epirubicin—liver cancer	0.00846	0.00865	CcSEcCtD
Linezolid—Vaginal moniliasis—Epirubicin—liver cancer	0.00822	0.0084	CcSEcCtD
Linezolid—Myelosuppression—Doxorubicin—liver cancer	0.00819	0.00837	CcSEcCtD
Linezolid—Hyponatraemia—Sorafenib—liver cancer	0.00818	0.00836	CcSEcCtD
Linezolid—Lactic dehydrogenase activity increased—Epirubicin—liver cancer	0.00811	0.00829	CcSEcCtD
Linezolid—Anorectal disorder—Epirubicin—liver cancer	0.00789	0.00807	CcSEcCtD
Linezolid—Vulvovaginal candidiasis—Epirubicin—liver cancer	0.00789	0.00807	CcSEcCtD
Linezolid—Rectal disorder—Doxorubicin—liver cancer	0.00783	0.008	CcSEcCtD
Linezolid—Peripheral vascular disorder—Doxorubicin—liver cancer	0.00783	0.008	CcSEcCtD
Linezolid—Vaginal moniliasis—Doxorubicin—liver cancer	0.00761	0.00778	CcSEcCtD
Linezolid—Vulvovaginal mycotic infection—Epirubicin—liver cancer	0.00759	0.00776	CcSEcCtD
Linezolid—Lactic dehydrogenase activity increased—Doxorubicin—liver cancer	0.0075	0.00767	CcSEcCtD
Linezolid—Blindness—Epirubicin—liver cancer	0.0075	0.00766	CcSEcCtD
Linezolid—Hypokalaemia—Sorafenib—liver cancer	0.00742	0.00758	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00734	0.0075	CcSEcCtD
Linezolid—Anorectal disorder—Doxorubicin—liver cancer	0.0073	0.00746	CcSEcCtD
Linezolid—Vulvovaginal candidiasis—Doxorubicin—liver cancer	0.0073	0.00746	CcSEcCtD
Linezolid—Gastritis—Sorafenib—liver cancer	0.00721	0.00737	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00719	0.00735	CcSEcCtD
Linezolid—Blood lactate dehydrogenase increased—Epirubicin—liver cancer	0.00714	0.0073	CcSEcCtD
Linezolid—Vulvovaginal mycotic infection—Doxorubicin—liver cancer	0.00702	0.00718	CcSEcCtD
Linezolid—Generalised oedema—Epirubicin—liver cancer	0.00698	0.00713	CcSEcCtD
Linezolid—Blindness—Doxorubicin—liver cancer	0.00694	0.00709	CcSEcCtD
Linezolid—Pancreatitis—Sorafenib—liver cancer	0.00691	0.00706	CcSEcCtD
Linezolid—Thrombocytosis—Epirubicin—liver cancer	0.00667	0.00682	CcSEcCtD
Linezolid—Blood lactate dehydrogenase increased—Doxorubicin—liver cancer	0.00661	0.00675	CcSEcCtD
Linezolid—Neutropenia—Sorafenib—liver cancer	0.00659	0.00673	CcSEcCtD
Linezolid—Oral candidiasis—Epirubicin—liver cancer	0.00653	0.00668	CcSEcCtD
Linezolid—Generalised oedema—Doxorubicin—liver cancer	0.00646	0.0066	CcSEcCtD
Linezolid—Pneumonia—Sorafenib—liver cancer	0.00632	0.00646	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00623	0.00636	CcSEcCtD
Linezolid—Thrombocytosis—Doxorubicin—liver cancer	0.00617	0.00631	CcSEcCtD
Linezolid—Renal failure—Sorafenib—liver cancer	0.00617	0.00631	CcSEcCtD
Linezolid—Neuropathy peripheral—Sorafenib—liver cancer	0.00616	0.00629	CcSEcCtD
Linezolid—Stomatitis—Sorafenib—liver cancer	0.00612	0.00626	CcSEcCtD
Linezolid—Oral candidiasis—Doxorubicin—liver cancer	0.00604	0.00618	CcSEcCtD
Linezolid—Haemoglobin—Sorafenib—liver cancer	0.00567	0.00579	CcSEcCtD
Linezolid—Haemorrhage—Sorafenib—liver cancer	0.00564	0.00576	CcSEcCtD
Linezolid—Fungal infection—Epirubicin—liver cancer	0.00537	0.00549	CcSEcCtD
Linezolid—Erythema multiforme—Sorafenib—liver cancer	0.00533	0.00545	CcSEcCtD
Linezolid—Skin ulcer—Epirubicin—liver cancer	0.00533	0.00545	CcSEcCtD
Linezolid—Tinnitus—Sorafenib—liver cancer	0.00526	0.00537	CcSEcCtD
Linezolid—Fungal infection—Doxorubicin—liver cancer	0.00497	0.00508	CcSEcCtD
Linezolid—Skin ulcer—Doxorubicin—liver cancer	0.00493	0.00504	CcSEcCtD
Linezolid—Erythema—Sorafenib—liver cancer	0.00491	0.00502	CcSEcCtD
Linezolid—Dysgeusia—Sorafenib—liver cancer	0.00481	0.00491	CcSEcCtD
Linezolid—Jaundice cholestatic—Epirubicin—liver cancer	0.00472	0.00483	CcSEcCtD
Linezolid—Muscle spasms—Sorafenib—liver cancer	0.00472	0.00482	CcSEcCtD
Linezolid—Anaemia—Sorafenib—liver cancer	0.00454	0.00464	CcSEcCtD
Linezolid—Glossitis—Epirubicin—liver cancer	0.0045	0.0046	CcSEcCtD
Linezolid—Angioedema—Sorafenib—liver cancer	0.00449	0.00458	CcSEcCtD
Linezolid—Leukopenia—Sorafenib—liver cancer	0.00439	0.00449	CcSEcCtD
Linezolid—Jaundice cholestatic—Doxorubicin—liver cancer	0.00437	0.00447	CcSEcCtD
Linezolid—Cough—Sorafenib—liver cancer	0.00428	0.00438	CcSEcCtD
Linezolid—Hypertension—Sorafenib—liver cancer	0.00424	0.00433	CcSEcCtD
Linezolid—Glossitis—Doxorubicin—liver cancer	0.00417	0.00426	CcSEcCtD
Linezolid—Vaginal inflammation—Epirubicin—liver cancer	0.00415	0.00424	CcSEcCtD
Linezolid—Dry mouth—Sorafenib—liver cancer	0.00409	0.00418	CcSEcCtD
Linezolid—Anaphylactic shock—Sorafenib—liver cancer	0.00401	0.00409	CcSEcCtD
Linezolid—Candida infection—Epirubicin—liver cancer	0.00396	0.00405	CcSEcCtD
Linezolid—Fluid retention—Epirubicin—liver cancer	0.00394	0.00403	CcSEcCtD
Linezolid—Thrombocytopenia—Sorafenib—liver cancer	0.00392	0.00401	CcSEcCtD
Linezolid—Vaginal infection—Epirubicin—liver cancer	0.00392	0.004	CcSEcCtD
Linezolid—Neuropathy—Epirubicin—liver cancer	0.0039	0.00398	CcSEcCtD
Linezolid—Skin disorder—Sorafenib—liver cancer	0.00389	0.00398	CcSEcCtD
Linezolid—Vaginal inflammation—Doxorubicin—liver cancer	0.00384	0.00392	CcSEcCtD
Linezolid—Anorexia—Sorafenib—liver cancer	0.00382	0.0039	CcSEcCtD
Linezolid—Ecchymosis—Epirubicin—liver cancer	0.00375	0.00383	CcSEcCtD
Linezolid—Candida infection—Doxorubicin—liver cancer	0.00367	0.00375	CcSEcCtD
Linezolid—Fluid retention—Doxorubicin—liver cancer	0.00365	0.00373	CcSEcCtD
Linezolid—Vaginal infection—Doxorubicin—liver cancer	0.00363	0.0037	CcSEcCtD
Linezolid—Neuropathy—Doxorubicin—liver cancer	0.00361	0.00368	CcSEcCtD
Linezolid—Sepsis—Epirubicin—liver cancer	0.0036	0.00368	CcSEcCtD
Linezolid—Dyspnoea—Sorafenib—liver cancer	0.00357	0.00365	CcSEcCtD
Linezolid—Dyspepsia—Sorafenib—liver cancer	0.00353	0.0036	CcSEcCtD
Linezolid—Phlebitis—Epirubicin—liver cancer	0.0035	0.00357	CcSEcCtD
Linezolid—Decreased appetite—Sorafenib—liver cancer	0.00348	0.00356	CcSEcCtD
Linezolid—Thrombophlebitis—Epirubicin—liver cancer	0.00348	0.00356	CcSEcCtD
Linezolid—Ecchymosis—Doxorubicin—liver cancer	0.00347	0.00355	CcSEcCtD
Linezolid—Gastrointestinal disorder—Sorafenib—liver cancer	0.00346	0.00353	CcSEcCtD
Linezolid—Fatigue—Sorafenib—liver cancer	0.00345	0.00353	CcSEcCtD
Linezolid—Constipation—Sorafenib—liver cancer	0.00343	0.0035	CcSEcCtD
Linezolid—Pain—Sorafenib—liver cancer	0.00343	0.0035	CcSEcCtD
Linezolid—Sepsis—Doxorubicin—liver cancer	0.00333	0.00341	CcSEcCtD
Linezolid—Cardiac failure congestive—Epirubicin—liver cancer	0.00332	0.00339	CcSEcCtD
Linezolid—Gastrointestinal pain—Sorafenib—liver cancer	0.00328	0.00335	CcSEcCtD
Linezolid—Phlebitis—Doxorubicin—liver cancer	0.00324	0.00331	CcSEcCtD
Linezolid—Thrombophlebitis—Doxorubicin—liver cancer	0.00322	0.00329	CcSEcCtD
Linezolid—Urticaria—Sorafenib—liver cancer	0.00318	0.00325	CcSEcCtD
Linezolid—Abdominal pain—Sorafenib—liver cancer	0.00317	0.00324	CcSEcCtD
Linezolid—Body temperature increased—Sorafenib—liver cancer	0.00317	0.00324	CcSEcCtD
Linezolid—Hypoglycaemia—Epirubicin—liver cancer	0.00309	0.00315	CcSEcCtD
Linezolid—Cardiac failure congestive—Doxorubicin—liver cancer	0.00307	0.00314	CcSEcCtD
Linezolid—Hyponatraemia—Epirubicin—liver cancer	0.00302	0.00309	CcSEcCtD
Linezolid—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00301	0.00308	CcSEcCtD
Linezolid—Asthenia—Sorafenib—liver cancer	0.00287	0.00294	CcSEcCtD
Linezolid—Hypoglycaemia—Doxorubicin—liver cancer	0.00286	0.00292	CcSEcCtD
Linezolid—Pruritus—Sorafenib—liver cancer	0.00283	0.0029	CcSEcCtD
Linezolid—Hyponatraemia—Doxorubicin—liver cancer	0.0028	0.00286	CcSEcCtD
Linezolid—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00279	0.00285	CcSEcCtD
Linezolid—Liver function test abnormal—Epirubicin—liver cancer	0.00278	0.00284	CcSEcCtD
Linezolid—Hypokalaemia—Epirubicin—liver cancer	0.00274	0.0028	CcSEcCtD
Linezolid—Diarrhoea—Sorafenib—liver cancer	0.00274	0.0028	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00271	0.00277	CcSEcCtD
Linezolid—Gastritis—Epirubicin—liver cancer	0.00267	0.00272	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00266	0.00272	CcSEcCtD
Linezolid—Dizziness—Sorafenib—liver cancer	0.00265	0.00271	CcSEcCtD
Linezolid—Eosinophilia—Epirubicin—liver cancer	0.00258	0.00263	CcSEcCtD
Linezolid—Liver function test abnormal—Doxorubicin—liver cancer	0.00257	0.00263	CcSEcCtD
Linezolid—Pancreatitis—Epirubicin—liver cancer	0.00255	0.00261	CcSEcCtD
Linezolid—Vomiting—Sorafenib—liver cancer	0.00255	0.0026	CcSEcCtD
Linezolid—Hypokalaemia—Doxorubicin—liver cancer	0.00254	0.00259	CcSEcCtD
Linezolid—Rash—Sorafenib—liver cancer	0.00253	0.00258	CcSEcCtD
Linezolid—Dermatitis—Sorafenib—liver cancer	0.00252	0.00258	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00251	0.00257	CcSEcCtD
Linezolid—Headache—Sorafenib—liver cancer	0.00251	0.00257	CcSEcCtD
Linezolid—Pancytopenia—Epirubicin—liver cancer	0.00247	0.00253	CcSEcCtD
Linezolid—Gastritis—Doxorubicin—liver cancer	0.00247	0.00252	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00246	0.00251	CcSEcCtD
Linezolid—Neutropenia—Epirubicin—liver cancer	0.00243	0.00249	CcSEcCtD
Linezolid—Upper respiratory tract infection—Epirubicin—liver cancer	0.00242	0.00247	CcSEcCtD
Linezolid—Eosinophilia—Doxorubicin—liver cancer	0.00239	0.00244	CcSEcCtD
Linezolid—Nausea—Sorafenib—liver cancer	0.00238	0.00243	CcSEcCtD
Linezolid—Pancreatitis—Doxorubicin—liver cancer	0.00236	0.00241	CcSEcCtD
Linezolid—Hyperglycaemia—Epirubicin—liver cancer	0.00235	0.0024	CcSEcCtD
Linezolid—Pneumonia—Epirubicin—liver cancer	0.00233	0.00239	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.0023	0.00235	CcSEcCtD
Linezolid—Pancytopenia—Doxorubicin—liver cancer	0.00229	0.00234	CcSEcCtD
Linezolid—Renal failure—Epirubicin—liver cancer	0.00228	0.00233	CcSEcCtD
Linezolid—Neuropathy peripheral—Epirubicin—liver cancer	0.00228	0.00233	CcSEcCtD
Linezolid—Stomatitis—Epirubicin—liver cancer	0.00226	0.00231	CcSEcCtD
Linezolid—Neutropenia—Doxorubicin—liver cancer	0.00225	0.0023	CcSEcCtD
Linezolid—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00224	0.00229	CcSEcCtD
Linezolid—Hyperglycaemia—Doxorubicin—liver cancer	0.00217	0.00222	CcSEcCtD
Linezolid—Pneumonia—Doxorubicin—liver cancer	0.00216	0.00221	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00213	0.00218	CcSEcCtD
Linezolid—Renal failure—Doxorubicin—liver cancer	0.00211	0.00216	CcSEcCtD
Linezolid—Neuropathy peripheral—Doxorubicin—liver cancer	0.00211	0.00215	CcSEcCtD
Linezolid—Haemoglobin—Epirubicin—liver cancer	0.00209	0.00214	CcSEcCtD
Linezolid—Stomatitis—Doxorubicin—liver cancer	0.00209	0.00214	CcSEcCtD
Linezolid—Haemorrhage—Epirubicin—liver cancer	0.00208	0.00213	CcSEcCtD
Linezolid—Hypoaesthesia—Epirubicin—liver cancer	0.00207	0.00212	CcSEcCtD
Linezolid—Pharyngitis—Epirubicin—liver cancer	0.00207	0.00211	CcSEcCtD
Linezolid—Erythema multiforme—Epirubicin—liver cancer	0.00197	0.00201	CcSEcCtD
Linezolid—Tinnitus—Epirubicin—liver cancer	0.00194	0.00199	CcSEcCtD
Linezolid—Haemoglobin—Doxorubicin—liver cancer	0.00194	0.00198	CcSEcCtD
Linezolid—Haemorrhage—Doxorubicin—liver cancer	0.00193	0.00197	CcSEcCtD
Linezolid—Hypoaesthesia—Doxorubicin—liver cancer	0.00192	0.00196	CcSEcCtD
Linezolid—Pharyngitis—Doxorubicin—liver cancer	0.00191	0.00196	CcSEcCtD
Linezolid—Chills—Epirubicin—liver cancer	0.00187	0.00191	CcSEcCtD
Linezolid—Erythema multiforme—Doxorubicin—liver cancer	0.00182	0.00186	CcSEcCtD
Linezolid—Erythema—Epirubicin—liver cancer	0.00181	0.00185	CcSEcCtD
Linezolid—Tinnitus—Doxorubicin—liver cancer	0.0018	0.00184	CcSEcCtD
Linezolid—Flatulence—Epirubicin—liver cancer	0.00179	0.00183	CcSEcCtD
Linezolid—Dysgeusia—Epirubicin—liver cancer	0.00178	0.00182	CcSEcCtD
Linezolid—Muscle spasms—Epirubicin—liver cancer	0.00174	0.00178	CcSEcCtD
Linezolid—Chills—Doxorubicin—liver cancer	0.00173	0.00177	CcSEcCtD
Linezolid—Vision blurred—Epirubicin—liver cancer	0.00171	0.00175	CcSEcCtD
Linezolid—Erythema—Doxorubicin—liver cancer	0.00168	0.00172	CcSEcCtD
Linezolid—Anaemia—Epirubicin—liver cancer	0.00168	0.00171	CcSEcCtD
Linezolid—Flatulence—Doxorubicin—liver cancer	0.00165	0.00169	CcSEcCtD
Linezolid—Dysgeusia—Doxorubicin—liver cancer	0.00164	0.00168	CcSEcCtD
Linezolid—Vertigo—Epirubicin—liver cancer	0.00163	0.00167	CcSEcCtD
Linezolid—Leukopenia—Epirubicin—liver cancer	0.00162	0.00166	CcSEcCtD
Linezolid—Muscle spasms—Doxorubicin—liver cancer	0.00161	0.00165	CcSEcCtD
Linezolid—Cough—Epirubicin—liver cancer	0.00158	0.00162	CcSEcCtD
Linezolid—Vision blurred—Doxorubicin—liver cancer	0.00158	0.00162	CcSEcCtD
Linezolid—Convulsion—Epirubicin—liver cancer	0.00157	0.00161	CcSEcCtD
Linezolid—Hypertension—Epirubicin—liver cancer	0.00157	0.0016	CcSEcCtD
Linezolid—Anaemia—Doxorubicin—liver cancer	0.00155	0.00159	CcSEcCtD
Linezolid—Dry mouth—Epirubicin—liver cancer	0.00151	0.00154	CcSEcCtD
Linezolid—Vertigo—Doxorubicin—liver cancer	0.00151	0.00154	CcSEcCtD
Linezolid—Leukopenia—Doxorubicin—liver cancer	0.0015	0.00154	CcSEcCtD
Linezolid—Anaphylactic shock—Epirubicin—liver cancer	0.00148	0.00151	CcSEcCtD
Linezolid—Cough—Doxorubicin—liver cancer	0.00146	0.0015	CcSEcCtD
Linezolid—Convulsion—Doxorubicin—liver cancer	0.00145	0.00149	CcSEcCtD
Linezolid—Thrombocytopenia—Epirubicin—liver cancer	0.00145	0.00148	CcSEcCtD
Linezolid—Hypertension—Doxorubicin—liver cancer	0.00145	0.00148	CcSEcCtD
Linezolid—Skin disorder—Epirubicin—liver cancer	0.00144	0.00147	CcSEcCtD
Linezolid—Hyperhidrosis—Epirubicin—liver cancer	0.00143	0.00146	CcSEcCtD
Linezolid—Anorexia—Epirubicin—liver cancer	0.00141	0.00144	CcSEcCtD
Linezolid—Dry mouth—Doxorubicin—liver cancer	0.0014	0.00143	CcSEcCtD
Linezolid—Anaphylactic shock—Doxorubicin—liver cancer	0.00137	0.0014	CcSEcCtD
Linezolid—Thrombocytopenia—Doxorubicin—liver cancer	0.00134	0.00137	CcSEcCtD
Linezolid—Insomnia—Epirubicin—liver cancer	0.00134	0.00137	CcSEcCtD
Linezolid—Skin disorder—Doxorubicin—liver cancer	0.00133	0.00136	CcSEcCtD
Linezolid—Paraesthesia—Epirubicin—liver cancer	0.00133	0.00136	CcSEcCtD
Linezolid—Hyperhidrosis—Doxorubicin—liver cancer	0.00132	0.00135	CcSEcCtD
Linezolid—Dyspnoea—Epirubicin—liver cancer	0.00132	0.00135	CcSEcCtD
Linezolid—Somnolence—Epirubicin—liver cancer	0.00132	0.00135	CcSEcCtD
Linezolid—Anorexia—Doxorubicin—liver cancer	0.00131	0.00133	CcSEcCtD
Linezolid—Dyspepsia—Epirubicin—liver cancer	0.0013	0.00133	CcSEcCtD
Linezolid—Decreased appetite—Epirubicin—liver cancer	0.00129	0.00132	CcSEcCtD
Linezolid—Gastrointestinal disorder—Epirubicin—liver cancer	0.00128	0.00131	CcSEcCtD
Linezolid—Fatigue—Epirubicin—liver cancer	0.00128	0.0013	CcSEcCtD
Linezolid—Pain—Epirubicin—liver cancer	0.00127	0.00129	CcSEcCtD
Linezolid—Constipation—Epirubicin—liver cancer	0.00127	0.00129	CcSEcCtD
Linezolid—Insomnia—Doxorubicin—liver cancer	0.00124	0.00127	CcSEcCtD
Linezolid—Paraesthesia—Doxorubicin—liver cancer	0.00123	0.00126	CcSEcCtD
Linezolid—Dyspnoea—Doxorubicin—liver cancer	0.00122	0.00125	CcSEcCtD
Linezolid—Somnolence—Doxorubicin—liver cancer	0.00122	0.00124	CcSEcCtD
Linezolid—Gastrointestinal pain—Epirubicin—liver cancer	0.00121	0.00124	CcSEcCtD
Linezolid—Dyspepsia—Doxorubicin—liver cancer	0.00121	0.00123	CcSEcCtD
Linezolid—Decreased appetite—Doxorubicin—liver cancer	0.00119	0.00122	CcSEcCtD
Linezolid—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00118	0.00121	CcSEcCtD
Linezolid—Fatigue—Doxorubicin—liver cancer	0.00118	0.00121	CcSEcCtD
Linezolid—Urticaria—Epirubicin—liver cancer	0.00118	0.0012	CcSEcCtD
Linezolid—Pain—Doxorubicin—liver cancer	0.00117	0.0012	CcSEcCtD
Linezolid—Constipation—Doxorubicin—liver cancer	0.00117	0.0012	CcSEcCtD
Linezolid—Body temperature increased—Epirubicin—liver cancer	0.00117	0.0012	CcSEcCtD
Linezolid—Abdominal pain—Epirubicin—liver cancer	0.00117	0.0012	CcSEcCtD
Linezolid—Gastrointestinal pain—Doxorubicin—liver cancer	0.00112	0.00114	CcSEcCtD
Linezolid—Urticaria—Doxorubicin—liver cancer	0.00109	0.00111	CcSEcCtD
Linezolid—Body temperature increased—Doxorubicin—liver cancer	0.00108	0.00111	CcSEcCtD
Linezolid—Abdominal pain—Doxorubicin—liver cancer	0.00108	0.00111	CcSEcCtD
Linezolid—Asthenia—Epirubicin—liver cancer	0.00106	0.00109	CcSEcCtD
Linezolid—Pruritus—Epirubicin—liver cancer	0.00105	0.00107	CcSEcCtD
Linezolid—Diarrhoea—Epirubicin—liver cancer	0.00101	0.00104	CcSEcCtD
Linezolid—MAOA—Oxidative Stress—NFE2L2—liver cancer	0.000983	0.0456	CbGpPWpGaD
Linezolid—Asthenia—Doxorubicin—liver cancer	0.000983	0.001	CcSEcCtD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000979	0.0454	CbGpPWpGaD
Linezolid—Dizziness—Epirubicin—liver cancer	0.000979	0.001	CcSEcCtD
Linezolid—Pruritus—Doxorubicin—liver cancer	0.000969	0.000991	CcSEcCtD
Linezolid—Vomiting—Epirubicin—liver cancer	0.000941	0.000962	CcSEcCtD
Linezolid—MAOA—Oxidative Stress—GPX3—liver cancer	0.000938	0.0435	CbGpPWpGaD
Linezolid—Diarrhoea—Doxorubicin—liver cancer	0.000937	0.000958	CcSEcCtD
Linezolid—Rash—Epirubicin—liver cancer	0.000934	0.000954	CcSEcCtD
Linezolid—Dermatitis—Epirubicin—liver cancer	0.000933	0.000953	CcSEcCtD
Linezolid—Headache—Epirubicin—liver cancer	0.000928	0.000948	CcSEcCtD
Linezolid—Dizziness—Doxorubicin—liver cancer	0.000906	0.000926	CcSEcCtD
Linezolid—MAOB—Biological oxidations—UGDH—liver cancer	0.000891	0.0413	CbGpPWpGaD
Linezolid—Nausea—Epirubicin—liver cancer	0.000879	0.000899	CcSEcCtD
Linezolid—Vomiting—Doxorubicin—liver cancer	0.000871	0.00089	CcSEcCtD
Linezolid—Rash—Doxorubicin—liver cancer	0.000864	0.000883	CcSEcCtD
Linezolid—Dermatitis—Doxorubicin—liver cancer	0.000863	0.000882	CcSEcCtD
Linezolid—Headache—Doxorubicin—liver cancer	0.000858	0.000877	CcSEcCtD
Linezolid—MAOB—Tryptophan metabolism—CYP2E1—liver cancer	0.000814	0.0378	CbGpPWpGaD
Linezolid—Nausea—Doxorubicin—liver cancer	0.000814	0.000832	CcSEcCtD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000615	0.0285	CbGpPWpGaD
Linezolid—MAOB—Tryptophan metabolism—CYP1A1—liver cancer	0.000585	0.0271	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—HMOX1—liver cancer	0.000585	0.0271	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—UGDH—liver cancer	0.000559	0.0259	CbGpPWpGaD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000534	0.0248	CbGpPWpGaD
Linezolid—MAOA—Melatonin metabolism and effects—CYP1A1—liver cancer	0.000531	0.0246	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—NR1H4—liver cancer	0.00052	0.0241	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—CYP1A1—liver cancer	0.000517	0.024	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTA3—liver cancer	0.000512	0.0237	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTA4—liver cancer	0.000468	0.0217	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTA2—liver cancer	0.000456	0.0212	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTA1—liver cancer	0.00044	0.0204	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—MAPK14—liver cancer	0.000436	0.0202	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—NAT2—liver cancer	0.000435	0.0202	CbGpPWpGaD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000383	0.0178	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—HPGDS—liver cancer	0.000348	0.0161	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000335	0.0155	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—NR1H4—liver cancer	0.000326	0.0151	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTA3—liver cancer	0.000321	0.0149	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GLUL—liver cancer	0.0003	0.0139	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTA4—liver cancer	0.000294	0.0136	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTA2—liver cancer	0.000286	0.0133	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—CYP2E1—liver cancer	0.000283	0.0132	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTA1—liver cancer	0.000276	0.0128	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—NAT2—liver cancer	0.000273	0.0127	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GGT1—liver cancer	0.00026	0.0121	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000241	0.0112	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTP1—liver cancer	0.000234	0.0108	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GLUL—liver cancer	0.00023	0.0107	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—HPGDS—liver cancer	0.000218	0.0101	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—GSTM1—liver cancer	0.000215	0.00997	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—CYP1A1—liver cancer	0.000204	0.00945	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—CYP2E1—liver cancer	0.000178	0.00825	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GGT1—liver cancer	0.000163	0.00758	CbGpPWpGaD
Linezolid—MAOB—Metabolism—UGDH—liver cancer	0.000152	0.00707	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTP1—liver cancer	0.000147	0.00681	CbGpPWpGaD
Linezolid—MAOB—Metabolism—EPT1—liver cancer	0.000143	0.00664	CbGpPWpGaD
Linezolid—MAOB—Metabolism—TAT—liver cancer	0.000136	0.0063	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—GSTM1—liver cancer	0.000135	0.00625	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—CYP1A1—liver cancer	0.000128	0.00593	CbGpPWpGaD
Linezolid—MAOA—Metabolism—UGDH—liver cancer	9.56e-05	0.00443	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GLUL—liver cancer	9.23e-05	0.00428	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CPT1B—liver cancer	9.23e-05	0.00428	CbGpPWpGaD
Linezolid—MAOA—Metabolism—EPT1—liver cancer	8.99e-05	0.00417	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NR1H4—liver cancer	8.9e-05	0.00413	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTA3—liver cancer	8.75e-05	0.00406	CbGpPWpGaD
Linezolid—MAOA—Metabolism—TAT—liver cancer	8.52e-05	0.00395	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—BRAF—liver cancer	8.34e-05	0.00387	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTA4—liver cancer	8e-05	0.00371	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTA2—liver cancer	7.8e-05	0.00362	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CASP3—liver cancer	7.63e-05	0.00354	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTA1—liver cancer	7.52e-05	0.00349	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NAT2—liver cancer	7.44e-05	0.00345	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—JUN—liver cancer	7.41e-05	0.00344	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CTNNB1—liver cancer	7.35e-05	0.00341	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ALDOB—liver cancer	7.13e-05	0.00331	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—RAF1—liver cancer	6.96e-05	0.00323	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CRABP1—liver cancer	6.8e-05	0.00316	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—VEGFA—liver cancer	6.47e-05	0.003	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—BRAF—liver cancer	6.39e-05	0.00296	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HPGDS—liver cancer	5.95e-05	0.00276	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CPT1B—liver cancer	5.79e-05	0.00269	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GLUL—liver cancer	5.79e-05	0.00269	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NR1H4—liver cancer	5.58e-05	0.00259	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TNF—liver cancer	5.55e-05	0.00257	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTA3—liver cancer	5.49e-05	0.00255	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—RAF1—liver cancer	5.33e-05	0.00248	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PSMD10—liver cancer	5.3e-05	0.00246	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PSMA4—liver cancer	5.3e-05	0.00246	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GOT2—liver cancer	5.16e-05	0.00239	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTA4—liver cancer	5.02e-05	0.00233	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTA2—liver cancer	4.89e-05	0.00227	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP2E1—liver cancer	4.85e-05	0.00225	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTA1—liver cancer	4.72e-05	0.00219	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NAT2—liver cancer	4.67e-05	0.00217	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYCS—liver cancer	4.54e-05	0.0021	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL6—liver cancer	4.48e-05	0.00208	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ALDOB—liver cancer	4.47e-05	0.00208	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GOT1—liver cancer	4.45e-05	0.00206	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GGT1—liver cancer	4.45e-05	0.00206	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CRABP1—liver cancer	4.27e-05	0.00198	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTP1—liver cancer	4e-05	0.00185	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HMOX1—liver cancer	3.94e-05	0.00183	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—HRAS—liver cancer	3.83e-05	0.00178	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HPGDS—liver cancer	3.73e-05	0.00173	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GSTM1—liver cancer	3.67e-05	0.0017	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP1A1—liver cancer	3.48e-05	0.00162	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PSMA4—liver cancer	3.33e-05	0.00154	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PSMD10—liver cancer	3.33e-05	0.00154	CbGpPWpGaD
Linezolid—MAOB—Metabolism—MTHFR—liver cancer	3.25e-05	0.00151	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GOT2—liver cancer	3.24e-05	0.0015	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PPARA—liver cancer	3.19e-05	0.00148	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP2E1—liver cancer	3.04e-05	0.00141	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—HRAS—liver cancer	2.94e-05	0.00136	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYCS—liver cancer	2.85e-05	0.00132	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GGT1—liver cancer	2.79e-05	0.0013	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GOT1—liver cancer	2.79e-05	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CG—liver cancer	2.73e-05	0.00127	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PPARG—liver cancer	2.63e-05	0.00122	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTP1—liver cancer	2.51e-05	0.00116	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HMOX1—liver cancer	2.47e-05	0.00115	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CD—liver cancer	2.4e-05	0.00111	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ALB—liver cancer	2.37e-05	0.0011	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GSTM1—liver cancer	2.31e-05	0.00107	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP1A1—liver cancer	2.19e-05	0.00101	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CB—liver cancer	2.09e-05	0.00097	CbGpPWpGaD
Linezolid—MAOA—Metabolism—MTHFR—liver cancer	2.04e-05	0.000945	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PPARA—liver cancer	2e-05	0.000927	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CG—liver cancer	1.71e-05	0.000794	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PPARG—liver cancer	1.65e-05	0.000766	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CD—liver cancer	1.5e-05	0.000698	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ALB—liver cancer	1.49e-05	0.000689	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CB—liver cancer	1.31e-05	0.000609	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CA—liver cancer	1.27e-05	0.000591	CbGpPWpGaD
Linezolid—MAOB—Metabolism—AKT1—liver cancer	1.04e-05	0.000483	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CA—liver cancer	8e-06	0.000371	CbGpPWpGaD
Linezolid—MAOA—Metabolism—AKT1—liver cancer	6.53e-06	0.000303	CbGpPWpGaD
